Integ. Proteins

What does Integ. Proteins do?

Integrated Proteins Ltd processes oil seeds in the Edible Oil industry and has a market cap of Rs 16 Cr. As of March 2025, it reported net sales of 21 Cr and a net profit of 0 Cr, with a P/E ratio of 16.00.

Overview: <BR>Integrated Proteins Ltd is engaged in the processing of various oil seeds and operates within the Edible Oil industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Integrated Proteins Limited was incorporated as a public limited company in October 1992. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 21 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market cap: Rs 16 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.01 <BR>Return on Equity: 9.58% <BR>Price to Book: 6.24<BR><BR>Contact Details: <BR>Address: City Point Opp Town Hall, Station Road Jamnagar Gujarat : 361008 <BR>Tel: 91-288-2551901/902/903 <BR>Email: ps@arcadia.co.in <BR>Website: http://www.integratedproteins.com

Has Integ. Proteins declared dividend?

No Dividend History Available

Who are the peers of the Integ. Proteins?

Peers of Integ. Proteins include Marico, Patanjali Foods, AWL Agri Business, Gokul Agro, and others. Marico shows excellent management and capital structure, while Integ. Proteins has average growth and a 1-year return of 129.69%.

Peers: The peers of Integ. Proteins are Marico, Patanjali Foods, AWL Agri Busine., Gokul Agro, Sundrop Brands, CIAN Agro, Natraj Proteins, Ashiana Agro Ind, and Signature Green.<BR><BR>Quality Snapshot: Excellent management risk is observed at Marico, while Average management risk is found at Patanjali Foods and Gokul Agro, and the rest have Below Average management risk. Growth is Excellent at Patanjali Foods and Gokul Agro, Good at AWL Agri Busine. and CIAN Agro, while Average growth is seen at Integ. Proteins, and the rest have Below Average growth. Excellent capital structure is noted at Marico and Sundrop Brands, Good at Patanjali Foods, AWL Agri Busine., and Gokul Agro, while Integ. Proteins and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: CIAN Agro has the highest 1-year return at 1037.81%, while AWL Agri Busine. has the lowest at -27.15%. Integ. Proteins has a 1-year return of 129.69%, which is significantly higher than AWL Agri Busine. Additionally, the six-month return is negative for AWL Agri Busine., Gokul Agro, Ashiana Agro Ind, and Integ. Proteins.

What is the technical trend for Integ. Proteins?

As of June 4, 2025, Integ. Proteins shows a mildly bearish trend, with bearish weekly MACD and moving averages, despite mixed signals from the monthly indicators.

As of 4 June 2025, the technical trend for Integ. Proteins has changed from does not qualify to mildly bearish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating a weakening momentum. The daily moving averages are also bearish, reinforcing the negative sentiment. The Bollinger Bands show a mildly bearish stance on the weekly chart, contrasting with a bullish outlook on the monthly chart. The KST is bearish on the weekly timeframe but bullish monthly, suggesting mixed signals. Overall, the current technical stance is mildly bearish, driven primarily by the bearish indicators on the MACD and moving averages.

Who are in the management team of Integ. Proteins?

As of March 2023, the management team of Integ. Proteins includes Vinod P Mehta (Chairman), Arvindbhai Kantilal Shah (Managing Director), Piyush Chimanalal Vora (CFO), and several independent and non-executive directors. They oversee the company's strategic direction and operations.

As of March 2023, the management team of Integ. Proteins includes the following individuals:<BR><BR>1. Vinod P Mehta - Chairman (Non-Executive) & Director (Non-Independent)<BR>2. Arvindbhai Kantilal Shah - Executive Director & Managing Director<BR>3. Piyush Chimanalal Vora - Executive Director & Chief Financial Officer<BR>4. Bhalchandra Vyas - Independent Non-Executive Director<BR>5. Vijaykumar Shamjibhai Dattani - Independent Non-Executive Director<BR>6. Neepa Praful Kothari - Non-Executive & Non-Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Who are the top shareholders of the Integ. Proteins?

The top shareholders of Integ. Proteins include Siddheshwar Advisory Private Limited with 23.89%, and promoter Vinod Prabhulal Mehta with 10.06%. Individual investors collectively hold 47.19%, with no institutional holdings or pledged shares reported.

The top shareholders of Integ. Proteins include Siddheshwar Advisory Private Limited, which holds the largest public share at 23.89%. The promoter with the highest individual holding is Vinod Prabhulal Mehta, who owns 10.06%. Additionally, individual investors collectively hold 47.19% of the company. There are no institutional holdings or pledged promoter shares reported.

How big is Integ. Proteins?

As of 21st July, Integrated Proteins Ltd has a market capitalization of 17.00 Cr, with net sales of 21.50 Cr and a net profit of 0.25 Cr in the latest four quarters. Specific values for Shareholder's Funds and Total Assets are unavailable.

As of 21st July, Integrated Proteins Ltd has a market capitalization of 17.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 21.50 Cr and a net profit of 0.25 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period, but specific values for Shareholder's Funds and Total Assets are unavailable.

Are Integ. Proteins latest results good or bad?

Integrated Proteins' latest results show a mixed performance with improved net sales and profit, but concerns remain due to thin operating margins, erratic revenue patterns, and negative return on capital employed. While there are signs of recovery, the overall instability suggests caution for potential investors.

The latest results for Integrated Proteins indicate a mixed performance. In Q2 FY26, the company reported net sales of ₹4.20 crores, a significant improvement from ₹0.00 crores in the previous quarter (Q1 FY26). Additionally, it achieved a net profit of ₹0.05 crores, compared to no profit in Q1 FY26. This marks a positive shift, as the company is emerging from a period of operational dormancy.<BR><BR>However, despite these improvements, the overall financial health of Integrated Proteins raises concerns. The operating margin remains very thin at just 2.14%, and the company has shown erratic revenue patterns, with a notable drop from ₹21.49 crores in Q4 FY25 to the current quarter's figures. This volatility suggests that the recent uptick in sales may not be sustainable.<BR><BR>Moreover, the company's return on equity (ROE) of 8.75% is better than its historical average, but the average return on capital employed (ROCE) remains negative, indicating ongoing challenges in generating value. The lack of institutional interest and the micro-cap status further complicate the outlook.<BR><BR>In summary, while there are signs of recovery with positive sales and profit figures, the overall performance is still characterized by instability and uncertainty, making it difficult to label the results as definitively good or bad. Caution is advised for potential investors.

Should I buy, sell or hold Integ. Proteins?

How has been the historical performance of Integ. Proteins?

Integ. Proteins has shown significant growth, with net sales reaching 21.50 Cr in March 2025, up from 0.24 Cr in March 2024. The company also reported increased operating profit, profit before tax, and profit after tax, alongside a rise in earnings per share to 0.71.

Answer:<BR>The historical performance of Integ. Proteins shows significant growth in net sales, reaching 21.50 Cr in March 2025, up from just 0.24 Cr in March 2024 and 0.17 Cr in March 2023. The total operating income also increased to 21.50 Cr in March 2025, compared to 0.24 Cr in the previous year. The company has seen a notable rise in operating profit, which stood at 0.34 Cr in March 2025, a substantial improvement from 0.14 Cr in March 2024. Profit before tax also increased to 0.32 Cr in March 2025, up from 0.10 Cr in March 2024, while profit after tax reached 0.25 Cr, compared to 0.09 Cr in the prior year. The earnings per share (EPS) rose to 0.71 in March 2025 from 0.26 in March 2024, reflecting a positive trend in profitability.<BR><BR>Breakdown:<BR>Integ. Proteins has demonstrated a remarkable upward trajectory in its financial performance over the past few years. Starting from no sales in previous years, the company achieved net sales of 21.50 Cr in March 2025, marking a significant increase from 0.24 Cr in March 2024. This growth is mirrored in the total operating income, which also reached 21.50 Cr in March 2025. The operating profit has turned positive, with a reported 0.34 Cr in March 2025, compared to a loss of 0.11 Cr in March 2024. Profit before tax and profit after tax have both shown substantial increases, reaching 0.32 Cr and 0.25 Cr respectively in March 2025, indicating improved profitability. The earnings per share have also risen to 0.71, reflecting the company's enhanced financial health. Overall, Integ. Proteins has transitioned from a period of minimal activity to a phase of significant growth and profitability.

Is Integ. Proteins overvalued or undervalued?

As of November 27, 2025, Integ. Proteins is considered undervalued with an attractive investment appeal, reflected in its favorable PE ratio of 42.60 and EV to EBITDA of 14.06, despite a year-to-date return of -49.13%, while showing a strong three-year return of 97.78%.

As of 27 November 2025, the valuation grade for Integ. Proteins has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company is currently considered undervalued. Key ratios include a PE ratio of 42.60, an EV to EBITDA of 14.06, and a PEG ratio of 0.11, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Integ. Proteins has a higher PE ratio than CIAN Agro, which stands at 33.9, but lower than Manorama Industries at 43.54. The EV to EBITDA ratio of Integ. Proteins is also more favorable than that of Manorama Industries, which is 28.15. Despite the recent underperformance in the stock's year-to-date return of -49.13% compared to the Sensex's 9.70%, the long-term performance over three years shows a remarkable return of 97.78%, reinforcing the potential for recovery and growth in value.

When is the next results date for Integrated Proteins Ltd?

The next results date for Integrated Proteins Ltd is 12 February 2026.

The next results date for Integrated Proteins Ltd is scheduled for 12 February 2026.

Which are the latest news on Integ. Proteins?

Why is Integrated Proteins Ltd falling/rising?

As of 11-Feb, Integrated Proteins Ltd's stock price is rising to Rs 28.16, up 5.0%, but has shown significant volatility and a poor performance over the past month and year-to-date. Despite today's increase, declining investor participation suggests underlying challenges.

As of 11-Feb, Integrated Proteins Ltd's stock price is rising, currently at Rs 28.16, reflecting an increase of Rs 1.34 or 5.0%. This rise is notable as the stock outperformed its sector by 0.88% today. Despite opening with a loss of 5% and experiencing a wide trading range of Rs 2.68, the stock managed to touch an intraday high of Rs 28.16. <BR><BR>However, it is important to note that the stock has shown significant volatility today, with an intraday volatility of 5%. Additionally, the stock's performance over the past month has been poor, with a decline of 13.46%, and it has experienced a year-to-date drop of 18.14%. The stock is currently trading higher than its 5-day moving averages but lower than its 20-day, 50-day, 100-day, and 200-day moving averages, indicating mixed performance trends.<BR><BR>Moreover, there has been a significant decline in investor participation, with delivery volume falling by 94.51% against the 5-day average. This could suggest a lack of confidence among investors despite the current rise in stock price. Overall, while the stock is experiencing a rise today, the broader context of its recent performance and investor behavior indicates underlying challenges.